OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
WPH$5.8555

Wattanapat Hospital Trang PCL

Healthcare Facilities & ServicesVerified

Wattanapat Hospital Trang PCL maintains a market price of THB 5.85, with a market capitalization of THB 4,177,639,808.55. The company's price-to-earnings ratio is 11.88, and its price-to-book ratio is 2.17, indicating a moderate valuation relative to its book value. The enterprise value to EBITDA ratio is 11.48, and the enterprise value to revenue ratio is 2.27, suggesting a relatively high valuation in terms of revenue. The company's profitability is reflected in its return on equity of 18.25% and return on assets of 9.82%, both of which are strong indicators of efficient capital use and asset management. The operating income of THB 459,498,610 and net income of THB 351,755,410 demonstrate solid earnings performance. However, the company's free cash flow is negative at THB -337,334,090, indicating that capital expenditures are outpacing operating cash flow. Wattanapat Hospital Trang PCL's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's total revenue of THB 2,329,850,480 is derived from its healthcare services, and there are no additional segments or regions reported in the financial data. The company's growth trajectory is supported by a strong operating cash flow of THB 535,185,860 and a capital expenditure of THB -861,075,640, indicating significant investment in infrastructure and facilities. The outlook for the current fiscal year suggests continued investment in the business, although the negative free cash flow may pose a challenge to sustaining growth without additional financing. The company faces a medium liquidity risk, as indicated by a current ratio of 0.97, which is slightly below 1. This suggests that the company may struggle to meet its short-term obligations with its current assets. Additionally, the debt-to-equity ratio of 0.64 indicates a moderate level of leverage, with long-term debt of THB 1,230,016,000. The risk assessment also notes that net cash is negative after subtracting total debt, which could signal potential liquidity constraints. Recent financial filings and transcripts do not indicate any major events or strategic shifts for Wattanapat Hospital Trang PCL. The company's financial performance and capital structure remain stable, with no significant changes reported in the latest disclosures.

30-day price · WPH-0.05 (-0.8%)
Low$5.55High$6.20Close$6.00As of12 May, 00:00 UTC
Profile
CompanyWattanapat Hospital Trang PCL
TickerWPH.BK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Wattanapat Hospital Trang PCL operates as a healthcare provider in Thailand, offering medical services and facilities to generate revenue through patient care and related healthcare activities.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92 based on verified market data.

Wattanapat Hospital Trang PCL maintains a market price of THB 5.85, with a market capitalization of THB 4,177,639,808.55. The company's price-to-earnings ratio is 11.88, and its price-to-book ratio is 2.17, indicating a moderate valuation relative to its book value. The enterprise value to EBITDA ratio is 11.48, and the enterprise value to revenue ratio is 2.27, suggesting a relatively high valuation in terms of revenue. The company's profitability is reflected in its return on equity of 18.25% and return on assets of 9.82%, both of which are strong indicators of efficient capital use and asset management. The operating income of THB 459,498,610 and net income of THB 351,755,410 demonstrate solid earnings performance. However, the company's free cash flow is negative at THB -337,334,090, indicating that capital expenditures are outpacing operating cash flow. Wattanapat Hospital Trang PCL's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's total revenue of THB 2,329,850,480 is derived from its healthcare services, and there are no additional segments or regions reported in the financial data. The company's growth trajectory is supported by a strong operating cash flow of THB 535,185,860 and a capital expenditure of THB -861,075,640, indicating significant investment in infrastructure and facilities. The outlook for the current fiscal year suggests continued investment in the business, although the negative free cash flow may pose a challenge to sustaining growth without additional financing. The company faces a medium liquidity risk, as indicated by a current ratio of 0.97, which is slightly below 1. This suggests that the company may struggle to meet its short-term obligations with its current assets. Additionally, the debt-to-equity ratio of 0.64 indicates a moderate level of leverage, with long-term debt of THB 1,230,016,000. The risk assessment also notes that net cash is negative after subtracting total debt, which could signal potential liquidity constraints. Recent financial filings and transcripts do not indicate any major events or strategic shifts for Wattanapat Hospital Trang PCL. The company's financial performance and capital structure remain stable, with no significant changes reported in the latest disclosures.
Key takeaways
  • The company has a strong return on equity of 18.25%, indicating efficient use of shareholder capital.
  • The enterprise value to revenue ratio of 2.27 suggests a relatively high valuation in terms of revenue.
  • The company's free cash flow is negative, indicating that capital expenditures are outpacing operating cash flow.
  • The debt-to-equity ratio of 0.64 indicates a moderate level of leverage.
  • The company's liquidity risk is medium, with a current ratio of 0.97.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTHB
Revenue$2.33B
Gross profit$769.6M
Operating income$459.5M
Net income$351.8M
R&D
SG&A
D&A
SBC
Operating cash flow$535.2M
CapEx-$861.1M
Free cash flow-$337.3M
Total assets$3.58B
Total liabilities$1.65B
Total equity$1.93B
Cash & equivalents$130.5M
Long-term debt$1.23B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$5.85
Market cap$4.18B
Enterprise value$5.28B
P/E11.9
Reported non-GAAP P/E
EV/Revenue2.3
EV/Op income11.5
EV/OCF9.9
P/B2.2
P/Tangible book2.2
Tangible book$1.93B
Net cash-$1.10B
Current ratio1.0
Debt/Equity0.6
ROA9.8%
ROE18.2%
Cash conversion1.5%
CapEx/Revenue-37.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricWPHActivity
Op margin19.7%18.2% medp25 18.2% · p75 24.6%above median
Net margin15.1%14.7% medp25 11.7% · p75 28.1%above median
Gross margin33.0%19.7% medp25 19.7% · p75 39.8%above median
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-37.0%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity64.0%71.3% medp25 19.0% · p75 91.7%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 14:19 UTC#05abe983
Market quoteclose THB 5.85 · shares 0.71B diluted
no public URL
2026-05-10 14:19 UTC#ab5fdb9d
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 14:22 UTCJob: c47da581